Company Deep Dive

Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.

View Deep Dive

600329.SS

STRONG BUYREMOVE

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited · Healthcare · China · $4.6B · Avg Vol: $23M/d

StockRank

P/E (TTM)

13.7x

ROE

27.5%

D/E

0.0x

Dividend %

12.5%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Traditional Chinese medicine player with localized regulatory risks and no global thematic tailwinds to support an asymmetric thesis.

COMPANY DESCRIPTION

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited researches, manufactures, and distributes Traditional Chinese Medicine (TCM) and modern pharmaceuticals. The company's competitive moat is anchored by its prestigious national-level secret formulas and iconic heritage brands like 'Da Ren Tang' and 'Guangyuanyuan'. It operates as a highly recognized, vertically integrated TCM leader with a robust distribution network across China.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	1.2B	1.2B	1.1B	727M	-15.8%
EPS	0.17	0.19	0.43	0.41	35.2%
Shares	773M	770M	770M	770M	-0.4%
Debt	38M	49M	4M	10M	-36.6%
Equity	964M	976M	1.2B	1.0B	2.9%
Op CF	100M	102M	137M	68M	-12.0%
Inv CF	-2M	-84M	51M	-208M	—
Fin CF	-35M	-123M	-47M	-145M	—

PRICE (1M)-8.7%

SMA 50SMA 200

$5.64

RSI (14)

40.8

52W High

$7.14

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

34.8%97.4

ROE

27.5%93.7

GP/Assets

31.8%67.8

Op. Margin

33.0%94.0

FCF/Assets

4.5%68.8

Piotroski

—55.8

Int. Cover

50.0x91.4

D/E Ratio

0.01x90.2

Current Ratio

2.16x40.2

Value

P/E (TTM)

13.7x77.7

EV/EBITDA

24.6x14.5

P/FCF

404.8x19.3

P/B

4.0x30.0

P/S

6.0x36.0

Div Yield

12.5%99.5

Momentum

52W High %

79%73.1

RS 6M

-21%54.4

SMA 50/200

0.95x49.6

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-36%11.0

Q Growth

13%55.7

FUNDAMENTALS

Market Cap

$4.6B

P/E (Forward)

21.4x

Gross Margin

74.5%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 600329.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
600329.SS	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited(you)	$4.6B	86	STRONG BUY
000999.SZ	China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.	$6.0B	86	STRONG BUY
600535.SS	Tasly Pharmaceutical Group Co., Ltd	$3.1B	86	STRONG BUY
000513.SZ	Livzon Pharmaceutical Group Inc.	$4.0B	93	STRONG BUY
2096.HK	Simcere Pharmaceutical Group Limited	$3.3B	91	STRONG BUY
002603.SZ	Shijiazhuang Yiling Pharmaceutical Co., Ltd.	$4.0B	96	STRONG BUY
000963.SZ	Huadong Medicine Co., Ltd	$7.5B	83	STRONG BUY
600062.SS	China Resources Double-Crane Pharmaceutical Co.,Ltd.	$2.6B	88	STRONG BUY
000423.SZ	Dong-E-E-Jiao Co., Ltd.	$4.8B	99	STRONG BUY
000739.SZ	Apeloa Pharmaceutical Co.,Ltd	$2.8B	91	STRONG BUY

Peer medians: ROE 4.7% · P/E 27.9x · Gross margin 52.9%

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) — Stock Score Summary

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) has a MoatMap StockRank of 86/100 based on Quality (78/100), Value (45/100), and Momentum (51/100) factor scores. The current signal is STRONG BUY. Traditional Chinese medicine player with localized regulatory risks and no global thematic tailwinds to support an asymmetric thesis.

Key Financial Metrics

Price	$5.64
Market Cap	$4.6B
P/E (TTM)	13.68
P/E (Forward)	21.39
Price/Book	3.96
Return on Equity	27.5%
Return on Invested Capital	34.8%
Debt/Equity	0.77
Gross Margin	74.5%
Operating Margin	33.0%
Revenue Growth	4.1%
Dividend Yield	12.5%
Free Cash Flow	$11M

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited’s (600329.SS) StockRank?: MoatMap’s StockRank for Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) is 86/100, with a Strong Buy signal. It is a composite of Quality (78), Value (45), and Momentum (51) factor ranks across MoatMap’s 19,000+ stock universe.
Does Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited have an economic moat?: Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) has a Quality factor score of 78/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited a buy, hold, or sell?: MoatMap’s current signal for Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) is Strong Buy, based on a StockRank of 86/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in?: Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).